vs
Side-by-side financial comparison of Climb Global Solutions, Inc. (CLMB) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Climb Global Solutions, Inc. is the larger business by last-quarter revenue ($182.4M vs $177.4M, roughly 1.0× Pacira BioSciences, Inc.). Climb Global Solutions, Inc. runs the higher net margin — 1.8% vs 1.6%, a 0.2% gap on every dollar of revenue. On growth, Climb Global Solutions, Inc. posted the faster year-over-year revenue change (32.1% vs 5.0%). Over the past eight quarters, Climb Global Solutions, Inc.'s revenue compounded faster (40.7% CAGR vs -0.2%).
Univar Solutions Inc. is a global chemical and ingredients distributor and provider of value-added services.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
CLMB vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $182.4M | $177.4M |
| Net Profit | $3.3M | $2.9M |
| Gross Margin | 14.5% | — |
| Operating Margin | 2.1% | 3.9% |
| Net Margin | 1.8% | 1.6% |
| Revenue YoY | 32.1% | 5.0% |
| Net Profit YoY | -9.5% | — |
| EPS (diluted) | $0.18 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $182.4M | $177.4M | ||
| Q4 25 | $193.8M | $196.9M | ||
| Q3 25 | $161.3M | $179.5M | ||
| Q2 25 | $159.3M | $181.1M | ||
| Q1 25 | $138.0M | $168.9M | ||
| Q4 24 | $161.8M | $187.3M | ||
| Q3 24 | $119.3M | $168.6M | ||
| Q2 24 | $92.1M | $178.0M |
| Q1 26 | $3.3M | $2.9M | ||
| Q4 25 | $7.0M | — | ||
| Q3 25 | $4.7M | $5.4M | ||
| Q2 25 | $6.0M | $-4.8M | ||
| Q1 25 | $3.7M | $4.8M | ||
| Q4 24 | $7.0M | — | ||
| Q3 24 | $5.5M | $-143.5M | ||
| Q2 24 | $3.4M | $18.9M |
| Q1 26 | 14.5% | — | ||
| Q4 25 | 15.4% | 79.5% | ||
| Q3 25 | 15.9% | 80.9% | ||
| Q2 25 | 16.5% | 77.4% | ||
| Q1 25 | 16.9% | 79.7% | ||
| Q4 24 | 19.3% | 78.7% | ||
| Q3 24 | 20.3% | 76.9% | ||
| Q2 24 | 20.2% | 75.1% |
| Q1 26 | 2.1% | 3.9% | ||
| Q4 25 | 4.9% | 1.2% | ||
| Q3 25 | 4.3% | 3.5% | ||
| Q2 25 | 5.0% | 4.7% | ||
| Q1 25 | 3.5% | 1.2% | ||
| Q4 24 | 7.2% | 13.2% | ||
| Q3 24 | 7.1% | -82.8% | ||
| Q2 24 | 4.6% | 15.9% |
| Q1 26 | 1.8% | 1.6% | ||
| Q4 25 | 3.6% | — | ||
| Q3 25 | 2.9% | 3.0% | ||
| Q2 25 | 3.7% | -2.7% | ||
| Q1 25 | 2.7% | 2.8% | ||
| Q4 24 | 4.3% | — | ||
| Q3 24 | 4.6% | -85.1% | ||
| Q2 24 | 3.7% | 10.6% |
| Q1 26 | $0.18 | $0.07 | ||
| Q4 25 | $1.51 | $0.05 | ||
| Q3 25 | $1.02 | $0.12 | ||
| Q2 25 | $1.30 | $-0.11 | ||
| Q1 25 | $0.81 | $0.10 | ||
| Q4 24 | $1.52 | $0.38 | ||
| Q3 24 | $1.19 | $-3.11 | ||
| Q2 24 | $0.75 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.8M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $118.4M | $653.9M |
| Total Assets | $458.8M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $41.8M | $144.3M | ||
| Q4 25 | $36.6M | $238.4M | ||
| Q3 25 | $49.8M | $246.3M | ||
| Q2 25 | $28.6M | $445.9M | ||
| Q1 25 | $32.5M | $493.6M | ||
| Q4 24 | $29.8M | $484.6M | ||
| Q3 24 | $22.1M | $453.8M | ||
| Q2 24 | $48.4M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $118.4M | $653.9M | ||
| Q4 25 | $116.6M | $693.1M | ||
| Q3 25 | $109.3M | $727.2M | ||
| Q2 25 | $105.2M | $757.8M | ||
| Q1 25 | $95.6M | $798.5M | ||
| Q4 24 | $90.6M | $778.3M | ||
| Q3 24 | $87.7M | $749.6M | ||
| Q2 24 | $79.8M | $879.3M |
| Q1 26 | $458.8M | $1.2B | ||
| Q4 25 | $460.2M | $1.3B | ||
| Q3 25 | $376.1M | $1.3B | ||
| Q2 25 | $420.7M | $1.5B | ||
| Q1 25 | $370.1M | $1.6B | ||
| Q4 24 | $469.2M | $1.6B | ||
| Q3 24 | $371.9M | $1.5B | ||
| Q2 24 | $302.8M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLMB
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
